Symphony Medical, Inc.
HCID Member | Medical Devices & Tech  Advamed Member
26051 Merit Circle Suite 102
Laguna Hills, CA 92653 USA
phone: (949) 215-3613
fax: (949) 348-1866
Symbol Private
Founded 2003
Employees 9
www.symphonymed.com
Research Sector Medical Devices & Tech
Summary Description
Biocompatible Polymers and Cell Therapies to Treat Heart Disease
Management
Raymond W. Cohen, Chief Executive Officer

Frank Ahmann, Chief Operating Officer

Sam Helgerson, Ph.D.,Chief Scientific Officer

Andy G. Hinson, V.P., Regulatory & Clinical Affairs

Rena Juliar, Director of Product Development

Robert Peterson, Director of Research

Norman Tarazona, D.V.M., Senior Director, Preclinical Development
Keywords
cardiology, atrial fibrillation, cardiac conduction, biopolymer, cardiothoracic surgery, postoperative atrial fibrillation, arrhythmia, heart failure, open heart surgery, congestive heart failure, chf

Comment | Printable Version | Oct. 20, 2008
If you work for Symphony Medical, Inc. and want to update this profile, click here

Description
Symphony Medical, Inc., is a privately held venture capital backed company with proprietary biopolymer and biotherapeutic devices directed toward Congestive Heart Failure (CHF) and post-operative atrial fibrillation (POAF).
Products / Services
The Company's Algisyl-LVR® product for treatment of CHF, is in the final stages of preclinical development with human clinical trials anticipated to begin in early 2009.
Technology / Differentiation
Symphony Medical's approach to treating CHF consists of administering an inert, biocompatible biopolymer to the left ventricular wall to re-shape and thicken it, thus improving pumping efficiency and reducing cardiac wall stress. In essence, the strategically placed biopolymer reconstructs or augments the dilated chamber so that it assumes its more natural, healthy form. The implanted material coexists permanently with the heart's muscle. The regulatory pathway as a device is clear, and the efficacy endpoints for the therapy are well defined.
Market / Customers
Presently CHF affects about 5 million Americans, the number of patients is expected to double by the year 2020 becoming the most common form of heart disease. The economic impact that now surpasses $29 billion per year is expected to rise accordingly. Approximately 60% of the cost is taken up by hospitalization-related expenses.
Competitors / Substitutes / Alternatives
The use of various drugs is aimed at improving symptoms and slow down the progression of the disease. Stem cells are also being used experimentally with marginal benefits to regenerate muscle. Lastly, a number of invasive devices and pump assist devices are being developed with mixed success to stop disease progression.
Strategy
A capital-efficient approach toward product development has allowed Symphony to achieve significant milestones by conducting the majority of research in the University setting and at commercial laboratories. The company's near-term goals include establishing the safety and efficacy of its biotherapeutics.
Status
Symphony expects to begin a first-in-man clinical study in early 2009 at the German Heart Center in Munich for its Algisyl-LVR product. The Company also will file an IDE in Q4 2008 for a U.S study for Algisyl-LVR.


2008-11-22-2546